Novartis takes aim at risky Parkinson’s target with $1.5bn UCB dealNovartis has licensed a potential drug for Parkinson’s from Belgium’s UCB that it thinks could be the first Share XNovartis takes aim at risky Parkinson’s target with $1.5bn UCB dealhttps://pharmaphorum.com/news/novartis-takes-aim-at-risky-parkinsons-target-with-1-5bn-ucb-deal/
Novartis may have found a buyer for Sandoz; reportJust a few weeks after Novartis revealed it was considering a sale of its generics business Sandoz, there Share XNovartis may have found a buyer for Sandoz; reporthttps://pharmaphorum.com/news/novartis-may-have-found-a-buyer-for-sandoz-report/
AbbVie’s Humira tops ICER’s list of unwarranted price hikes againWith drug pricing controls back on the legislative table in the US, the influential Institute for Clinical and Share XAbbVie’s Humira tops ICER’s list of unwarranted price hikes againhttps://pharmaphorum.com/news/abbvies-humira-tops-icers-list-of-unwarranted-price-hikes-again/
Merck’s oral PCSK9 drug matches injectables in early trialsInjectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Share XMerck’s oral PCSK9 drug matches injectables in early trialshttps://pharmaphorum.com/news/mercks-oral-pcsk9-drug-matches-injectables-in-early-trials/
Swiss socialists say government should buy SandozSwitzerland’s Social Democratic Party has argued that the government should step in and acquire Novartis’ generics unit Sandoz Share XSwiss socialists say government should buy Sandozhttps://pharmaphorum.com/news/swiss-socialists-say-government-should-buy-sandoz/
Novartis’ iptacopan hits the mark in rare kidney disease C3GNovartis has chalked up another successful trial for its targeted factor B inhibitor iptacopan, an orally-active drug trying Share XNovartis’ iptacopan hits the mark in rare kidney disease C3Ghttps://pharmaphorum.com/news/novartis-iptacopan-hits-the-mark-in-rare-kidney-disease-c3g/
Novartis finally sells Roche stake, for almost $21 billionAfter more than 20 years, Novartis has finally decided to sell its substantial share in fellow Swiss pharma Share XNovartis finally sells Roche stake, for almost $21 billionhttps://pharmaphorum.com/news/novartis-finally-sells-roche-stake-for-almost-21-billion/
Pharma group will develop ‘digital endpoint’ for atopic dermatitisThe development of digital medicine requires valid endpoints that can be used in clinical trials, and a consortium Share XPharma group will develop ‘digital endpoint’ for atopic dermatitishttps://pharmaphorum.com/news/pharma-group-will-develop-digital-endpoint-for-atopic-dermatitis/
UK biotech Dunad inks $1.3bn Novartis deal for its protein degradersIn only its second year of operations, Cambridge, UK startup Dunad Therapeutics has already attracted a big pharma Share XUK biotech Dunad inks $1.3bn Novartis deal for its protein degradershttps://pharmaphorum.com/news/uk-biotech-dunad-inks-1-3bn-novartis-deal-for-its-protein-degraders/
